Wellington Partners
GTX medical and NeuroRecovery Technologies today announced their merger to create a leading global company committed to developing novel neuromodulation therapies to improve functional recovery of people with Spinal Cord Injuries (SCI). The merged entity will be known as GTX medical BV. The Christopher & Dana Reeve Foundation will be a shareholder in the merged company, alongside current investors including LSP, Inkef, Wellington Partners and GIMV. Ian Curtis will join the Board of Directors.
Themis announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine. The vaccine candidate is based on Themis’ proprietary measles vector platform, which includes exclusively licensed technology from Institut Pasteur. It was initially developed by Institut Pasteur as part of the ZIKAVAX consortium, coordinated by the European Vaccine Initiative (EVI) and including Themis and the Commissariat à l’énergie atomique et aux énergies alternatives (CEA).
AMBOSS has secured €30 million in Series B funding led by Partech’s growth fund, with Target Global acting as a co-investor. Existing investors Cherry Ventures, Wellington Partners and Holtzbrinck Digital also participated in the new financing round. With the new funding, AMBOSS will accelerate the global rollout of its knowledge platform and further invest in its smart guidance application to improve daily clinical decision-making for both generalist and specialist doctors.
Page 3 of 26
